As anticipated by the Board of Directors of Orion Corporation in the outlook for the year provided in the financial statements release in February, the entacapone product purchases by the marketing partner Novartis have been relatively high during the first months of the year. As the deliveries to Novartis are, however, expected to level off in the further course of the year, there is no reason to change the full-year outlook provided for Orion Pharma in February.
At the end of June 2006, Orion Corporation will demerge into two new companies, which is why no Group-level full-year outlook has been given by the Board of Directors. The outlook estimates for the new companies will be presented in connection with the publication of the listing prospectuses.
The decisions of the AGM will be communicated in a stock exchange release later today, after the meeting.
The Interim Report 1-3/2006 of the Orion Group will be published on Monday, 8 May 2006.
Jukka Viinanen Olli Huotari
CEO General Counsel
Jukka Viinanen, President and CEO, Orion Corporation, phone +358 10 429 3710
Jari Karlson, CFO, Orion Group, phone +358 50 429 2883
Orionintie 1A, 02200 Espoo